Founder
Leuko
Leuko Labs is developing PointCheck™, a non-invasive device that uses light to monitor white blood cell levels by imaging blood cells in superficial capillaries. This technology enables frequent testing for millions of immunosuppressed patients, reducing the risk of infection without the need for blood draws.
- Artificial Intelligence
- Digital Health
- Hardware
- Healthcare Technology
Updated 6 months ago
Funding
Raised to date
$4.5MRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Funding rounds are not available yet.
Founders
Product
Problem
Immunocompromised patients, such as those undergoing chemotherapy, are at high risk of infection, requiring frequent monitoring of white blood cell (WBC) levels. Current WBC monitoring methods rely on blood draws, which are invasive, inconvenient, and can delay time-sensitive treatment adjustments. This creates a need for a non-invasive, point-of-care solution for WBC monitoring.
Solution
Leuko Labs is developing PointCheck™, a non-invasive device that uses light to monitor white blood cell levels by imaging blood cells in superficial capillaries. The device is designed for at-home use and provides results in minutes without the need for a blood draw. By eliminating the need for blood samples, PointCheck™ enables more frequent testing, allowing for earlier detection of dangerously low WBC levels and timely preventative treatments, ultimately improving quality of life and clinical outcomes for immunosuppressed patients. The device employs artificial intelligence (AI) algorithms to analyze the images and determine WBC levels.
Target Audience
The primary target audience includes immunocompromised patients, particularly those undergoing chemotherapy, and the healthcare providers who manage their care.
Features
- Non-invasive WBC monitoring via imaging of blood cells in superficial capillaries
- Portable, finger-based device designed for at-home use
- Results provided in minutes
- AI-powered analysis of images to determine WBC levels
- Intended to identify elevated risk of infection in immunocompromised patients